Bedfont announces launch of 2nd generation NObreath at ERS 2018, Paris
Bedfont Scientific Ltd. launches their new FeNO monitor exclusively at the world’s largest European Respiratory Society Congress.
Medical device manufacturer, Bedfont, specialising in breath analysis for 40+ years, have announced a new and improved 2nd generation NObreath. The monitor will be launched at ERS, the world’s largest European Respiratory Society Congress, taking place September 15-19th in Paris.
The FeNO monitor will launch after the recent publication of NICE guidance on Asthma: diagnosis, monitoring and chronic asthma management. Put in place to improve asthma care, including the NObreath FeNO monitor from Bedfont as a recommended device1,2.
To celebrate the exclusive launch, the second-generation family business will also be holding a competition at their stand where delegates will have the chance to be entered into a prize draw to win a new NObreath.
Jason Smith, Managing Director, comments, “As a breath analysis medical device manufacturer who exports globally, ERS is a key congress for us to reconnect with our customers from around the world. We are thrilled to be launching the 2nd generation NObreath exclusively at ERS this year as we feel it would be quite symbolic; this launch will bring the product full circle, as the very first NObreath was too launched at an ERS Congress 11 years ago. We’re excited to show our customers what’s in store for the advancement of respiratory care.”
1. Asthma: diagnosis, monitoring and chronic asthma management | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2018 [cited 24 April 2018]. Available from: https://www.nice.org.uk/guidance/ng80
2. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2014 [cited 24 April 2018]. Available from: https://www.nice.org.uk/guidance/dg12
Media release date: 12th September 2018